Operative Strategien bei terminaler Herzinsuffizienz

S. Ensminger; T. Puehler; U. Schulz; U. Fuchs; M. Schönbrodt; M. Morshuis; J. Börgermann; K. Hakim-Meiboudi; J. Gummert

doi:10.1055/s-0034-1368474

Aktuelle Kardiologie, Inhaltsverzeichnis

Aktuelle Kardiologie 2014; 3(3): 179-187
DOI: 10.1055/s-0034-1368474

Übersichtsarbeit

Georg Thieme Verlag KG Stuttgart · New York

Operative Strategien bei terminaler Herzinsuffizienz

Therapeutic Options in End-Stage Heart Failure

S. Ensminger

Herz-und Diabeteszentrum Nordrhein-Westfalen, Klinik für Thorax und Kardiovaskularchirurgie, Universitätsklinikum der Ruhr-Universität Bochum, Bad Oeynhausen

,

T. Puehler

Herz-und Diabeteszentrum Nordrhein-Westfalen, Klinik für Thorax und Kardiovaskularchirurgie, Universitätsklinikum der Ruhr-Universität Bochum, Bad Oeynhausen

,

U. Schulz

Herz-und Diabeteszentrum Nordrhein-Westfalen, Klinik für Thorax und Kardiovaskularchirurgie, Universitätsklinikum der Ruhr-Universität Bochum, Bad Oeynhausen

,

U. Fuchs

Herz-und Diabeteszentrum Nordrhein-Westfalen, Klinik für Thorax und Kardiovaskularchirurgie, Universitätsklinikum der Ruhr-Universität Bochum, Bad Oeynhausen

,

M. Schönbrodt

Herz-und Diabeteszentrum Nordrhein-Westfalen, Klinik für Thorax und Kardiovaskularchirurgie, Universitätsklinikum der Ruhr-Universität Bochum, Bad Oeynhausen

,

M. Morshuis

Herz-und Diabeteszentrum Nordrhein-Westfalen, Klinik für Thorax und Kardiovaskularchirurgie, Universitätsklinikum der Ruhr-Universität Bochum, Bad Oeynhausen

,

J. Börgermann

Herz-und Diabeteszentrum Nordrhein-Westfalen, Klinik für Thorax und Kardiovaskularchirurgie, Universitätsklinikum der Ruhr-Universität Bochum, Bad Oeynhausen

,

K. Hakim-Meiboudi

Herz-und Diabeteszentrum Nordrhein-Westfalen, Klinik für Thorax und Kardiovaskularchirurgie, Universitätsklinikum der Ruhr-Universität Bochum, Bad Oeynhausen

,

J. Gummert

Herz-und Diabeteszentrum Nordrhein-Westfalen, Klinik für Thorax und Kardiovaskularchirurgie, Universitätsklinikum der Ruhr-Universität Bochum, Bad Oeynhausen

› Institutsangaben

Abstract

Zusammenfassung

In fast allen westlichen industrialisierten Ländern betrifft die terminale Herzinsuffizienz immer mehr Menschen. Nach wie vor ist die orthotope Herztransplantation dabei die „chirurgische“ Therapie der Wahl. Der Mangel an Spenderorganen und der technische Fortschritt führten in den letzten 20 Jahren zu chirurgischen organerhaltenden Strategien und Therapien, mit denen eine anstehende Herztransplantation hinausgezögert oder sogar vermieden werden kann. Heute können bestimmte Patienten mit ischämischer Kardiomyopathie oder Mitralklappeninsuffizienz trotz deutlich reduzierter Ventrikelfunktion mit einem akzeptablen Risiko operiert werden. Zusätzlich ist der Mitraclip für diese Patienten eine weitere therapeutische Alternative. Außerdem wurden Rekonstruktionsverfahren des linken Ventrikels in großen klinischen Studien wie RESTORE oder STICH untersucht – und werden kontrovers diskutiert. Weiterentwickelte Herzunterstützungssysteme werden nicht nur als Überbrückungssysteme zur Herztransplantation angewendet, sondern auch als Dauertherapie bei terminaler Herzinsuffizienz. In der vorliegenden Übersichtsarbeit werden die verschiedenen Verfahren, insbesondere deren Anwendung, Differenzialindikation und Komplikationen erläutert.

Abstract

Throughout almost all western industrialized nations an increasing number of patients are affected by terminal heart failure. Cardiac transplantation still remains the gold standard for the treatment of end-stage patients. However, motivated by an ever increasing organ donor shortage and supported by technical progress and innovations in cardiac surgery, a number of new innovative approaches such as resyncronisation and organ sparing strategies have been further developed to delay or finally avoid the need of heart transplantation. Therefore, a considerable number of patients suffering from ischemic cardiomyopathy or mitral valve regurgitation can nowadays be treated with conventional heart surgery, consisting of myocardial revascularization associated with surgical ventricular restoration and correction of mitral valve regurgitation at an acceptable operative risk. In addition Mitraclip represents an alternative therapeutic option for these patients. Left ventricular reconstruction techniques have been evaluated in recent multicenter trials such as RESTORE or STICH and since its publication, data have started a controversial discussion. Technical advances in handling and durability of the newer generation of ventricular assist devices have expanded their use from a “bridge to transplantation” therapy to destination therapy. This article will provide an overview of current therapeutic options in end-stage heart failure and will also give a short outlook on future perspectives.

Schlüsselwörter

Kardiomyopathie - Herztransplantation - Assistsysteme - Mitralklappenchirurgie - Koronarrevaskularisation - linksventrikuläre Ventrikelreduktion

Key words

cardiomyopathy - cardiac transplantation - ventricular assist device - myocardial revascularization - left ventricular reconstruction - destination therapy

Volltext

Referenzen

Literatur
1 Hunt SA, Abraham WT, Chin MH et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391-e479
2 Swedberg K, Cleland J, Dargie H et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): The Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 1115-1140
3 Shearn DL, Brent BN. Coronary artery bypass surgery in patients with left ventricular dysfunction. Am J Med 1986; 80: 405-411
4 Kron IL, Flanagan TL, Blackbourne LH et al. Coronary revascularization rather than cardiac transplantation for chronic ischemic cardiomyopathy. Ann Surg 1989; 210: 348-352
5 Yoshida K, Gould KL. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularization. J Am Coll Cardiol 1993; 22: 984-997
6 Montalescot G, Faraggi M, Drobinski G et al. Myocardial viability in patients with Q wave myocardial infarction and no residual ischemia. Circulation 1992; 86: 47-55
7 Hausmann H, Ennker J, Topp H et al. Coronary artery bypass grafting and heart transplantation in end-stage coronary artery disease: a comparison of hemodynamic improvement and ventricular function. J Card Surg 1994; 9: 77-84
8 Hausmann H, Topp H, Siniawski H et al. Decision-making in end-stage coronary artery disease: revascularization or heart transplantation?. Ann Thorac Surg 1997; 64: 1296-1301
9 Sedlis SP, Ramanathan KB, Morrison DA et al. Outcome of percutaneous coronary intervention versus coronary bypass grafting for patients with low left ventricular ejection fractions, unstable angina pectoris, and risk factors for adverse outcomes with bypass (the AWESOME Randomized Trial and Registry). Am J Cardiol 2004; 94: 118-120
10 Elefteriades JA, Tolis jr. G, Levi E et al. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol 1993; 22: 1411-1417
11 Elefteriades J, Edwards R. Coronary bypass in left heart failure. Semin Thorac Cardiovasc Surg 2002; 14: 125-132
12 McMurray JJ, Adamopoulos S, Anker SD et al. ESC Committee for Practice Guidelines. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847
13 Smolens IA, Pagani FD, Bolling SF. Mitral valve repair in heart failure. Eur J Heart Fail 2000; 2: 365-371
14 Bach DS, Bolling SF. Improvement following correction of secondary mitral regurgitation in end-stage cardiomyopathy with mitral annuloplasty. Am J Cardiol 1996; 78: 966-969
15 Bolling SF, Pagani FD, Deeb GM et al. Intermediate-term outcome of mitral reconstruction in cardiomyopathy. J Thorac Cardiovasc Surg 1998; 115: 381-386 discussion 387–388
16 Bolling SF. Mitral valve reconstruction in the patient with heart failure. Heart Fail Rev 2001; 6: 177-185
17 Bolling SF, Dickstein ML, Levy JH et al. Management strategies for high-risk cardiac surgery: improving outcomes in patients with heart failure. Heart Surg Forum 2000; 3: 337-349
18 Chen FY, Adams DH, Aranki SF et al. Mitral valve repair in cardiomyopathy. Circulation 1998; 98: II124-II127
19 Enriquez-Sarano M, Akins CW, Vahanian A. Mitral regurgitation. Lancet 2009; 373: 1382-1394
20 De Bonis M, Ferrara D, Taramasso M et al. Mitral replacement or repair for functional mitral regurgitation in dilated and ischemic cardiomyopathy: is it really the same?. Ann Thorac Surg 2012; 94: 44-51
21 Acker MA, Parides MK, Perrault LP et al. Mitral-valve repair versus replacement for severe ischemic mitral regurgitation. N Engl J Med 2014; 370: 23-32
22 Mauri L, Foster E, Glower DD et al. EVEREST II Investigators. 4-year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. J Am Coll Cardiol 2013; 62: 317-328
23 Taramasso M, Maisano F, Latib A et al. Clinical outcomes of MitraClip for the treatment of functional mitral regurgitation. EuroIntervention 2014; [Epub ahead of print]
24 Dor V, Saab M, Coste P et al. Left ventricular aneurysm: a new surgical approach. Thorac Cardiovasc Surg 1989; 37: 11-19
25 Athanasuleas CL, Stanley jr. AW, Buckberg GD et al. Surgical anterior ventricular endocardial restoration (SAVER) in the dilated remodeled ventricle after anterior myocardial infarction. RESTORE group. Reconstructive Endoventricular Surgery, returning Torsion Original Radius Elliptical Shape to the LV. J Am Coll Cardiol 2001; 37: 1199-1209
26 Athanasuleas CL, Buckberg GD, Stanley AW et al. Surgical ventricular restoration in the treatment of congestive heart failure due to post-infarction ventricular dilation. J Am Coll Cardiol 2004; 44: 1439-1445
27 Jones RH, Velazquez EJ, Michler RE et al. STICH Hypothesis 2 Investigators. Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 2009; 360: 1705-1717
28 Buckberg GD, Athanasuleas CL, Wechsler AS et al. The STICH trial unravelled. Eur J Heart Fail 2010; 12: 1024-1027
29 Lund LH, Edwards LB, Kucheryavaya AY et al. International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report–2013; focus theme: age. J Heart Lung Transplant 2013; 32: 951-964
30 Gummert JF, Funkat AK, Beckmann A et al. Cardiac surgery in Germany during 2010: a report on behalf of the German Society for Thoracic and Cardiovascular Surgery. Thorac Cardiovasc Surg 2011; 59: 259-267
31 Klotz S, Deng MC, Hanafy D et al. Reversible pulmonary hypertension in heart transplant candidates – pretransplant evaluation and outcome after orthotopic heart transplantation. Eur J Heart Fail 2003; 5: 645-653
32 Pauliks LB, Pietra BA, DeGroff CG et al. Non-invasive detection of acute allograft rejection in children by tissue Doppler imaging: myocardial velocities and myocardial acceleration during isovolumic contraction. J Heart Lung Transplant 2005; 24 (Suppl. 07) S239-S248
33 Deng MC, Eisen HJ, Mehra MR et al. Noninvasive discrimination of rejection in cardiac allograft recipients using gene expression profiling. Am J Transplant 2006; 6: 150-160
34 Stewart S, Winters GL, Fishbein MC et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710-1720
35 Aliabadi A, Cochrane AB, Zuckermann AO. Current strategies and future trends in immunosuppression after heart transplantation. Curr Opin Organ Transplant 2012; 17: 540-545
36 Eisen HJ, Kobashigawa J, Starling RC et al. Everolimus versus mycophenolate mofetil in heart transplantation: a randomized, multicenter trial. Am J Transplant 2013; 13: 1203-1216
37 Deng MC, Edwards LB, Hertz MI et al. International Society for Heart and Lung Transplantation. Mechanical circulatory support device database of the International Society for Heart and Lung Transplantation: third annual report–2005. J Heart Lung Transplant 2005; 24: 1182-1187
38 Kirklin JK, Naftel DC, Kormos RL et al. Third INTERMACS Annual Report: the evolution of destination therapy in the United States. J Heart Lung Transplant 2011; 30: 115-123
39 Kirklin JK, Naftel DC, Pagani FD et al. Long-term mechanical circulatory support (destination therapy): on track to compete with heart transplantation?. J Thorac Cardiovasc Surg 2012; 144: 584-603 discussion 597–598
40 Rose EA, Gelijns AC, Moskowitz AJ et al. Long-term mechanical left ventricular assistance for endstage heart failure. N Engl J Med 2001; 345: 1435-1443
41 Lietz K, Long JW, Kfoury AG et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era: implications for patient selection. Circulation 2007; 116: 497-505
42 Sheikh FH, Russell SD. HeartMate® II continuous-flow left ventricular assist system. Expert Rev Med Devices 2011; 8: 11-21
43 Park SJ, Milano CA, Tatooles AJ et al. HeartMate II Clinical Investigators. Outcomes in advanced heart failure patients with left ventricular assist devices for destination therapy. Circ Heart Fail 2012; 5: 241-248
44 Starling RC, Moazami N, Silvestry SC et al. Unexpected abrupt increase in left ventricular assist device thrombosis. N Engl J Med 2014; 370: 33-40
45 Birschmann I, Dittrich M, Eller T et al. Ambient hemolysis and activation of coagulation is different between HeartMate II and HeartWare left ventricular assist devices. J Heart Lung Transplant 2014; 33: 80-87
46 Lalonde SD, Alba AC, Rigobon A et al. Clinical differences between continuous flow ventricular assist devices: a comparison between HeartMate II and HeartWare HVAD. J Card Surg 2013; 28: 604-610
47 Strueber M, OʼDriscoll G, Jansz P et al. Multicenter evaluation of an intrapericardial left ventricular assist system. J Am Coll Cardiol 2011; 57: 1375-1382
48 Slaughter MS, Pagani FD, McGee EC et al. HeartWare ventricular assist system for bridge to transplant: combined results of the bridge to transplant and continued access protocol trial. J Heart Lung Transplant 2013; 32: 675-683
49 Aissaoui N, Börgermann J, Gummert J. Morshuis HeartWare continuous-flow ventricular assist device thrombosis: the Bad Oeynhausen experience. J Thorac Cardiovasc Surg 2012; 143: e37-e39
50 Copeland JG, Smith RG, Arabia FA et al. Cardiac replacement with a total artificial heart as a bridge to transplantation. N Engl J Med 2004; 351: 859-867
51 Copeland JG. SynCardia Total Artificial Heart: update and future. Tex Heart Inst J 2013; 40: 587-588